Valuation : Pacific Software Inc

Market Cap 48.82M 42.07M 39.83M 36.1M 67.73M 4.66B 68.07M 473M 182M 2.37B 183M 179M 7.5B P/E 2019
-2.65x
P/E 2020 -41.2x
Enterprise Value 49.19M 42.38M 40.13M 36.37M 68.24M 4.7B 68.59M 477M 183M 2.39B 185M 181M 7.55B EV / Sales 2019
-
EV / Sales 2020 2,435,972,350x
Free-Float
64%
Yield 2019 *
-
Yield 2020 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 10/06/2026
Director TitleAgeSince
Chairman 74 22/10/2016
Change 5-day change 1-year change 3-year change Capi.($)
-0.71%-6.35%-4.87%+9.03% 46.05B
-0.49%-3.36%+338.95%+517.49% 43.59B
+1.22%-2.72%+36.60%+20.97% 42.35B
+1.73%-3.42%+3.08%+65.37% 38.86B
-1.44%-4.76%+10.26%+38.52% 32.24B
+0.20%-2.82% - - 17.16B
+1.75%+0.42%+19.33%+112.55% 16.28B
-0.31%-2.78%+10.47%+30.49% 14.32B
+2.38%-2.85%+75.46%+40.38% 13.03B
Average +0.37%-4.76%+61.16%+104.35% 29.32B
Weighted average by Cap. +0.12%-5.10%+72.95%+123.36%

Financials

2019 2020
Net sales - 0.02 0.02 0.02 0.01 0.03 1.91 0.03 0.19 0.07 0.97 0.08 0.07 3.07
Net income -21.11M -18.19M -17.22M -15.61M -29.29M -2.02B -29.44M -205M -78.66M -1.03B -79.29M -77.55M -3.24B -1.17M -1.01M -958K -868K -1.63M -112M -1.64M -11.38M -4.38M -57.08M -4.41M -4.31M -180M
Net Debt -101K -86.64K -82.03K -74.36K -139K -9.61M -140K -974K -375K -4.89M -378K -369K -15.44M 367K 317K 300K 272K 510K 35.1M 512K 3.56M 1.37M 17.86M 1.38M 1.35M 56.44M
Logo Pacific Software Inc
PurMinds Enterprises, Inc., formerly Pacific Software, Inc., is a precision neuro-medicine development company pursuing solutions to neurological and psychiatric disorders. The Company's clinical pipeline includes neuroprotective compounds that restore neuronal functions and can address multiple clinical indications with significant unmet patient needs. The Company is focused on a 4P Medicine platform, in strategic partnership with SpectroChip Global Inc., for early detection and intervention of conditions before irreversible damage occurs. The Company operates under a Health Canada issued Controlled Drugs and Substances License. It has developed a pipeline of proprietary formulations and novel small molecules (NCEs). The Company's pipeline includes PUR100 Series and PUR500 Series.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!